<DOC>
	<DOCNO>NCT00659178</DOCNO>
	<brief_summary>The purpose study identify dose SB-485232 safe , tolerable biologically active use combination pegylated liposomal doxorubicin ( Doxil ) patient epithelial ovarian cancer . This study use standard treatment regimen pegylated liposomal doxorubicin ( Doxil ) combination rise dos SB-485232 . The dose select study use future study evaluate efficacy combination .</brief_summary>
	<brief_title>Combination Study Of SB-485232 ( Interleukin 18 ) And Doxil For Advanced Stage Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Female , age ≥18 year age ; 2 . Histologically confirm diagnosis epithelial ovarian , fallopian tube , primary peritoneal carcinoma ; 3 . Candidate receive pegylated liposomal doxorubicin treatment advance stage ovarian cancer per standard care opinion treat principal investigator ; 4 . Measurable lesion ( ) accord RECIST v1.0 ; 5 . ECOG performance status 0 , 1 2 ; 6 . Predicted life expectancy ≥4 month 7 . No chemotherapy , immunotherapy , hormonal therapy , biological therapy cancer , radiotherapy , surgical procedure ( except minor surgical procedure ) within four week begin treatment SB485232 ( six week nitrosoureas mitomycin C ) . Subjects must recover toxicity ( incur result previous therapy ) sufficiently enter Phase I study ; 8 . Diseasefree period least five year prior malignancy ( except curatively treat basal squamous cell carcinoma skin and/or carcinoma cervix situ ) ; 9 . Left ventricular ejection fraction ( LVEF ) ≥50 % determine MUGA scan ; 10 . A signed date write informed consent form obtain subject ; 11 . The subject able understand comply protocol requirement , timetable , instruction protocolstated restriction ; 12 . The subject likely maintain good venous blood access PK PD sample throughout study ; 13 . A female eligible enter participate study : nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , childbearing potential , negative serum pregnancy test screen visit , agree one several GSK acceptable contraceptive method ; 14 . Adequate organ function define : ANC ≥1.5 x 10^9/L ; hemoglobin ≥9 g/dL ( transfusion need ) ; platelet ≥75 x 10^9/L . 1 . Significant cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal autoimmune condition opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial ; 2 . Any severe concurrent disease condition , include significant active autoimmune disease rheumatoid arthritis , judgment principal investigator , would make subject inappropriate study participation ; 3 . History myocardial infarction , unstable angina , acute coronary syndrome within past six month ; 4 . The subject history hypersensitivity reaction conventional formulation doxorubicin HCl component pegylated liposomal doxorubicin ; 5 . The subject history receive total cumulative dosage doxorubicin HCl exceed currently recommend limit 550 mg/m^2 exceed 550 mg/m^2 dosage limit course current study . A subject also exclude receive lower cumulative dosage doxorubicin HCl ( i.e. , 400 mg/m^2 ) also prior radiotherapy mediastinal area concomitant therapy potentially cardiotoxic agent cyclophosphamide . Prior use anthracyclines anthracenediones include calculation total cumulative doxorubicin HCl dosage ; 6 . Women pregnant breastfeeding ; 7 . Corrected QT interval ( QTc ) ≥480 msec ( average three measurement make screen ) ; 8 . The subject diabetes mellitus poor glycemic control ; 9 . The subject history human immunodeficiency virus ( HIV ) immunodeficiency disease ; 10 . The subject positive Hepatitis B surface antigen ; 11 . The subject history severe infusionrelated reaction follow treatment pegylated liposomal doxorubicin describe protocol ; 12 . The subject acute infection severe uncontrolled infection require systemic antibiotic therapy ; 13 . Any serious medical psychiatric disorder would interfere subject safety inform consent ; 14 . Psychological , familial , sociological , geographical condition permit compliance protocol ; 15 . Known leptomeningeal disease evidence prior current metastatic brain disease . Routine screen central nervous system ( CNS ) image study ( CT MRI ) require clinically indicate ; 16 . Receiving concurrent chemotherapy , immunotherapy , radiotherapy , investigational therapy ; 17 . Oral corticosteroid within 14 day study entry ; 18 . History ventricular arrhythmia require drug device therapy ; 19 . Any investigational drug within 30 day five halflives ( whichever longer ) precede first dose SB485232 ; 20 . The subject active sign bowel obstruction .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Doxil ,</keyword>
	<keyword>pegylated liposomal doxorubicin ,</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>IL-18 ,</keyword>
	<keyword>combination study ,</keyword>
	<keyword>immunotherapy ,</keyword>
	<keyword>cytokine ,</keyword>
</DOC>